Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems.

Tapia F, Jordan I, Genzel Y, Reichl U.

PLoS One. 2017 Aug 24;12(8):e0182553. doi: 10.1371/journal.pone.0182553. eCollection 2017.

2.

Propagation of Brazilian Zika virus strains in static and suspension cultures using Vero and BHK cells.

Nikolay A, Castilho LR, Reichl U, Genzel Y.

Vaccine. 2017 Mar 23. pii: S0264-410X(17)30324-9. doi: 10.1016/j.vaccine.2017.03.018. [Epub ahead of print]

3.

Ezrin and HNRNP expression correlate with increased virus release rate and early onset of virus-induced apoptosis of MDCK suspension cells.

Kluge S, Genzel Y, Laus K, Serve A, Pflugmacher A, Peschel B, Rapp E, Reichl U.

Biotechnol J. 2016 Oct;11(10):1332-1342. doi: 10.1002/biot.201600384.

PMID:
27581796
4.

Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.

Tapia F, Vázquez-Ramírez D, Genzel Y, Reichl U.

Appl Microbiol Biotechnol. 2016 Mar;100(5):2121-32. doi: 10.1007/s00253-015-7267-9. Epub 2016 Jan 13. Review.

5.

Bioreactor concepts for cell culture-based viral vaccine production.

Gallo-Ramírez LE, Nikolay A, Genzel Y, Reichl U.

Expert Rev Vaccines. 2015;14(9):1181-95. doi: 10.1586/14760584.2015.1067144. Epub 2015 Jul 15. Review.

PMID:
26178380
6.

Increased titer and reduced lactate accumulation in recombinant retrovirus production through the down-regulation of HIF1 and PDK.

Rodrigues AF, Guerreiro MR, Formas-Oliveira AS, Fernandes P, Blechert AK, Genzel Y, Alves PM, Hu WS, Coroadinha AS.

Biotechnol Bioeng. 2016 Jan;113(1):150-62. doi: 10.1002/bit.25691. Epub 2015 Sep 2.

PMID:
26134455
7.

Vaccine Technology V: The art of taking vaccines to disease prevention.

Palomares LA, Buckland BC, Genzel Y, Cox MM.

Vaccine. 2015 Aug 20;33(35):4219-20. doi: 10.1016/j.vaccine.2015.06.098. Epub 2015 Jun 29. No abstract available.

PMID:
26133049
8.

Production of canine adenovirus type 2 in serum-free suspension cultures of MDCK cells.

Castro R, Fernandes P, Laske T, Sousa MF, Genzel Y, Scharfenberg K, Alves PM, Coroadinha AS.

Appl Microbiol Biotechnol. 2015 Sep;99(17):7059-68. doi: 10.1007/s00253-015-6636-8. Epub 2015 May 21.

PMID:
25994255
9.

Designing cell lines for viral vaccine production: Where do we stand?

Genzel Y.

Biotechnol J. 2015 May;10(5):728-40. doi: 10.1002/biot.201400388. Epub 2015 Apr 22. Review.

PMID:
25903999
10.

Monitoring changes in proteome during stepwise adaptation of a MDCK cell line from adherence to growth in suspension.

Kluge S, Benndorf D, Genzel Y, Scharfenberg K, Rapp E, Reichl U.

Vaccine. 2015 Aug 20;33(35):4269-80. doi: 10.1016/j.vaccine.2015.02.077. Epub 2015 Apr 16.

PMID:
25891398
11.

The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis.

Lohr V, Hädicke O, Genzel Y, Jordan I, Büntemeyer H, Klamt S, Reichl U.

BMC Biotechnol. 2014 Jul 30;14:72. doi: 10.1186/1472-6750-14-72.

12.

The influence of cell growth and enzyme activity changes on intracellular metabolite dynamics in AGE1.HN.AAT cells.

Rath AG, Rehberg M, Janke R, Genzel Y, Scholz S, Noll T, Rose T, Sandig V, Reichl U.

J Biotechnol. 2014 May 20;178:43-53. doi: 10.1016/j.jbiotec.2014.03.012. Epub 2014 Mar 18.

PMID:
24657347
13.

High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.

Genzel Y, Vogel T, Buck J, Behrendt I, Ramirez DV, Schiedner G, Jordan I, Reichl U.

Vaccine. 2014 May 19;32(24):2770-81. doi: 10.1016/j.vaccine.2014.02.016. Epub 2014 Feb 25.

PMID:
24583003
14.

Vaccine production: upstream processing with adherent or suspension cell lines.

Genzel Y, Rödig J, Rapp E, Reichl U.

Methods Mol Biol. 2014;1104:371-93. doi: 10.1007/978-1-62703-733-4_23.

PMID:
24297427
15.

Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor.

Tapia F, Vogel T, Genzel Y, Behrendt I, Hirschel M, Gangemi JD, Reichl U.

Vaccine. 2014 Feb 12;32(8):1003-11. doi: 10.1016/j.vaccine.2013.11.044. Epub 2013 Nov 19.

PMID:
24269322
16.

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.

Jordan I, Lohr V, Genzel Y, Reichl U, Sandig V.

Microorganisms. 2013 Nov 1;1(1):100-121. Review.

17.

Changes in intracellular metabolite pools during growth of adherent MDCK cells in two different media.

Rehberg M, Rath A, Ritter JB, Genzel Y, Reichl U.

Appl Microbiol Biotechnol. 2014 Jan;98(1):385-97. doi: 10.1007/s00253-013-5329-4. Epub 2013 Oct 31.

PMID:
24169951
18.

Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line.

Peschel B, Frentzel S, Laske T, Genzel Y, Reichl U.

Vaccine. 2013 Nov 19;31(48):5693-9. doi: 10.1016/j.vaccine.2013.09.051. Epub 2013 Oct 8.

PMID:
24113260
19.

Continuous influenza virus production in cell culture shows a periodic accumulation of defective interfering particles.

Frensing T, Heldt FS, Pflugmacher A, Behrendt I, Jordan I, Flockerzi D, Genzel Y, Reichl U.

PLoS One. 2013 Sep 5;8(9):e72288. doi: 10.1371/journal.pone.0072288. eCollection 2013.

20.

PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia.

Tung S, Shi Y, Wong K, Zhu F, Gorczynski R, Laister RC, Minden M, Blechert AK, Genzel Y, Reichl U, Spaner DE.

Blood. 2013 Aug 8;122(6):969-80. doi: 10.1182/blood-2013-03-489468. Epub 2013 Jun 27.

Supplemental Content

Loading ...
Support Center